How Various Breast Cancer Screening Guidelines Compare

Slideshow

In this slideshow, various clinical guidelines on breast cancer screening are summarized, including the ACP's recent recommendations that have come under some scrutiny.

According to the National Cancer Institute, breast cancer is the second most common cause of cancer-related death among women in the United States. Screening can help to find cancer at an early stage, when treatment is most effective and cure is more likely. Key professional organizations have published various clinical guidelines regarding when and how often to screen women at average and high-risk for breast cancer. However, their recommendations are not always concordant. The American College of Physicians (ACP) recently released new screening guidelines for average-risk women that have come under some scrutiny. This slideshow highlights the ACP’s updated guidance as well as several other breast cancer screening recommendations from key healthcare organizations and societies.

Recent Videos
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
ADCs demonstrate superior efficacy vs chemotherapy but maintain a similar efficacy profile that requires multidisciplinary collaboration to optimally treat.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content